Polaryx Therapeutics (PLYX) EPS (Basic) (2025 - 2026)
Polaryx Therapeutics (PLYX) posted quarterly EPS (Basic) of -$0.05 for Q1 2026, up 52.72% year-over-year from -$0.04 in Q1 2025, and up 52.72% quarter-over-quarter from -$0.11 in Q1 2025.
Polaryx Therapeutics (PLYX) EPS (Basic) (2025 - 2026) Analysis & Trends
Polaryx Therapeutics (PLYX) has reported EPS (Basic) for 2 consecutive years, with -$0.05 the latest figure, recorded in Q1 2026.
- In Q1 2026, EPS (Basic) rose 52.72% year-over-year to -$0.05; the TTM figure through Mar 2026 stood at -$0.16 (changed N/A YoY), while the FY2025 annual figure was -$0.31, down 16.11% from the prior year.
- EPS (Basic) climbed to -$0.05 in Q1 2026 per PLYX's latest filing, from -$0.11 in the prior quarter.
- Across five years, EPS (Basic) topped out at -$0.05 in Q1 2026 and bottomed at -$0.11 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | 1.23 |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | -0.72 |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | -0.06 |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 0.18 |
| 10 | Polaryx Therapeutics | 103.80 Mn | 92.26 Mn | - | -0.03 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.03 |
| Mar 31, 2026 | -0.05 |
| Mar 31, 2025 | -0.11 |